Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

UK study supports use of high-potency statin after heart attack

Heart attack patients who are subsequently prescribed a high-potency statin have a better chance of long-term survival than patients given simvastatin, but a survival benefit is not observed with statin/ezetimibe combinations, according to the results of a retrospective observational study (Heart, online 19 February 2014).

The authors of the study used the UK General Practice Research Database (see Panel) to analyse outcomes for patients admitted to hospital with a heart attack for the first time. The findings show a mortality benefit associated with a switch to a high-potency statin and are in accordance with results from previous randomised trials comparing high-dose statins with low to moderate doses for patients with acute coronary syndrome and coronary artery disease.

Sotiris Antoniou, consultant pharmacist in cardiovascular medicine at Barts Health NHS Trust, described the study as “interesting” and said it was representative of real-life practice. He added that the findings clearly support guidance from the National Institute for Health and Care Excellence: “Anyone admitted with acute coronary syndrome should be considered for high intensity statin therapy and, with atorvastatin now generic, there really should not be any practice that does not recommend atorvastatin 80mg as first-line management,” he said.

Lead author Chim Lang, consultant cardiologist and clinical pharmacologist at the University of Dundee Medical School, pointed out that there is a lot of interest in ezetimibe for heart patients. He added that there is evidence that the drug is effective at lowering cholesterol, but its effect on survival is unknown. Ezetimibe’s effect on cardiovascular events in combination with simvastatin is currently being tested in the IMPROVE-IT trial, the study authors highlight.

Speaking about the results of the current study, Dr Lang said: “Those who had ezetimibe added [to their statin treatment] did not appear to have a better outcome. So for the moment, the data support the use of high-potency statins.”

However, the researchers add that the results should be interpreted with caution because the number of patients receiving ezetimibe was smaller than the other two groups and the confidence intervals were large (see Panel).

Another recent study, a meta-analysis from the US, suggested that ezetimibe combined with a low to medium dose of statin could be an alternative treatment for patients who could not tolerate the side effects of, or who did not respond to, high-intensity statins. However, the authors warned that there were no long-term outcome data to support this.

Study design and results

Researchers used the UK General Practice Research Database to collect all records of patients who had suffered a heart attack and survived the following 30-day period. Patients were included in the study if they had been started on a statin therapy for the first time in those 30 days. They were then divided into three groups: those who received simvastatin (n=6,990), those who began with simvastatin and were switched to a high-potency statin (n=1,883) and those who received a statin plus ezetimibe (n=724). Patients were followed up for an average of 3.2 years.

High-potency statins, either rosuvastatin or atorvastatin, were associated with a reduced risk of death compared with simvastatin monotherapy (hazard ratio 0.72, 95 per cent confidence interval 0.59–0.88; P<0.001). But the statin/ezetimibe combination was not associated with a reduced risk of death compared with simvastatin monotherapy (HR 0.96, 95 per cent CI 0.64–1.43).  

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11134984

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Chris Gallagher/Science Photo Library

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.